NextCure Announces New Appointments to its Board of Directors BELTSVILLE, Md.

Announces New Appointments to its Board of Directors

BELTSVILLE, Md., October 4, 2021 - NextCure, Inc. (Nasdaq:

NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat

cancer and other immune-related diseases, today announced the appointments of Ellen G. Feigal, M.D., and Anne Borgman, M.D., to its Board

"I am thrilled to welcome two new members to NextCure's

Board of Directors," said Michael Richman, NextCure's president and chief executive officer. "Both Dr. Feigal and Dr.

Borgman bring extensive experience in clinical and biopharmaceutical settings. Their insights will be valuable as NextCure continues to

advance multiple clinical programs and investigate and develop new immunomedicines for cancer patients. These appointments follow the

resignation of Stella Xu, Ph.D. from the board as previously announced. In addition, we would like to thank Stella Xu for her commitment

and support in building NextCure."

Dr. Feigal is currently a Partner and Head of the Biologics Practice

at NDA Partners LLC, a life sciences consulting and contract development organization, where she leads efforts in designing and executing

product development and regulatory strategies in the areas of cell therapies, medical imaging, hematology and oncology. Dr. Feigal is

also adjunct faculty at the Sandra Day O'Connor College of Law, Arizona State University, where she teaches FDA drug law and medical research

ethics and law. Her career includes over thirty years in clinical drug development, with roles spanning industry and academic medicine,

including at the National Cancer Institute, where she served as Acting Director, Division of Cancer Treatment/Diagnosis during her tenure;

Senior Vice President of Research and Development at the California Institute of Regenerative Medicine, and Executive Medical Director,

global development at Amgen. She currently serves as a board member for Xencor. She earned her M.D. from the University of California,

Davis, completed an internal medicine residency at Stanford University and a hematology/oncology fellowship at the University of California,

Dr. Borgman is currently Vice President and Global Therapeutic Area

Lead, Hematology-Oncology, at Jazz Pharmaceuticals, where she is responsible for global development of the company's oncology and

hematology drugs, including four marketed products. Previously, Dr. Borgman was Vice President, Clinical Research & Development, at

Exelixis, where she was a Clinical Lead in the global development for cabozantinib in oncology indications including renal cell, hepatocellular

and thyroid carcinoma. Earlier she was Chief Medical Officer and Vice President of Hana Biosciences (Talon Therapeutics), where she oversaw

all aspects of the company's drug development operations. In addition, Dr. Borgman has worked as Associate Chief Medical Officer

at KaloBios Pharmaceuticals, and she was formerly a Global Development Head at Abbott Pharmaceuticals (now AbbVie) where she was responsible

for the early drug development of the PARP inhibitor, antimitotic, and Bcl-2/Bcl-XL platforms. Dr. Borgman continues clinical involvement,

as a Consulting Associate Professor at Stanford University School of Medicine's Stem Cell Transplant & Cell Biology program,

and as a Clinical Associate at University of Chicago's Department of Pediatric Oncology and Stem Cell Research. Dr. Borgman completed

her fellowship in pediatric hematology - oncology and stem cell transplant at UCLA David Geffen School of Medicine, trained in pediatrics

at Texas Children's Hospital, Baylor College of Medicine, and earned her M.D. from Loyola University of Chicago's Stritch School

About NextCure, Inc.

NextCure is a clinical-stage biopharmaceutical company committed to

discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary

FIND-IO platform, we study various immune cells to discover and understand targets and structural components of immune cells and

their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do

not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately

addressed by available therapies. http://www.nextcure.com

Cautionary Statement Regarding Forward-Looking Statements

Statements made in this press release that are not historical facts

are forward-looking statements. Words such as "expects," "believes," "intends," "hope,"

"forward" and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements

in this press release include, among others, statements about NextCure's plans, objectives and intentions with respect to the discovery

of immunomedicine targets and the discovery and development of immunomedicines. Forward-looking statements involve substantial risks

and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks

and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant

losses; our need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; and

the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. More detailed information

on these and additional factors that could affect NextCure's actual results are described in NextCure's filings with the

Securities and Exchange Commission (the "SEC"), including NextCure's most recent Form 10-K and subsequent Form 10-Q.

You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements,

even if expectations change.

Timothy Mayer, Ph.D.

Chief Operating Officer